Inventor
YARLAGADDA S. BABU
Inventor
US
Overview
Patents· 34 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
C07DHeterocyclic compounds23%
C07BGeneral methods of organic chemistry7%
A23LFoods, foodstuffs or non-alcoholic beverages, not otherwise provided for6%
A23VIndexing scheme relating to foods, foodstuffs or non-alcoholic beverages and lactic or propionic acid bacteria used in foodstuffs or food preparation6%
Y02ATechnologies for adaptation to climate change4%
C07CAcyclic or carbocyclic compounds1%
C07HSugars1%
C07KPeptides1%
PatentTitleYear
12,590,068Crystalline salts of a plasma kallikrein inhibitor202612,590,069Crystalline salts of a plasma kallikrein inhibitor202612,558,341Oral complement factor D inhibitors202612,552,750Crystalline salts of a plasma kallikrein inhibitor202612,545,646Crystalline salts of a plasma kallikrein inhibitor202612,545,645Crystalline salts of a plasma kallikrein inhibitor202612,545,647Crystalline salts of a plasma kallikrein inhibitor202612,508,266Methods and compositions for inhibition of polymerase202512,503,443Process-scale synthesis of a plasma kallikrein inhibitor202512,485,109Pyrrolo 12.3-dipyrimidine compounds and analogues thereof202512,472,197Methods, compositions, and dosing regimens for treatment of SARS-CoV-2 infections202512,344,585Crystalline salts of a plasma kallikrein inhibitor202512,162,838Human plasma kallikrein inhibitors202412,121,503Antiviral treatments202412,116,346Human plasma kallikrein inhibitors202412,054,492Imidazole-containing inhibitors of ALK2 kinase202412,043,610Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors202411,975,003Methods and compositions for treatment of Zika virus infection202411,866,418Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors202411,807,605Human plasma kallikrein inhibitors202311,708,332Human plasma kallikrein inhibitors202311,708,333Human plasma kallikrein inhibitors202311,708,347Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors202311,685,721Human plasma kallikrein inhibitors202311,661,426Imidazole-containing inhibitors of ALK2 kinase202311,618,733Crystalline salts of a plasma kallikrein inhibitor202311,618,731Prodrugs of kallikrein inhibitors202311,559,515Indole compounds and analogues thereof202311,464,755Antiviral treatments202211,370,774Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors202211,230,530Human plasma kallikrein inhibitors202211,203,574Human plasma kallikrein inhibitors202111,192,861Human plasma kallikrein inhibitors202111,173,159Methods and compositions for inhibition of polymerase2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to BIOCRYST PHARM INC (32)· patent assignee history
2021–2026Based in US· patent location history
2025Patents assigned to ISLAND PHARMACEUTICALS LTD (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BIOCRYST PHARM INC | 32 | 2021–2026 |
| ISLAND PHARMACEUTICALS LTD | 2 | 2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 34 | 2021–2026 |